Integrating Brain, Neurocognitive, and Computational Tools in Opioid Use Disorder (OUD) to Characterize Executive Function and to Predict Clinical Outcomes

Integrating Brain, Neurocognitive, and Computational Tools in Opioid Use Disorder (OUD) to Characterize Executive Function and to Predict Clinical Outcomes

Brief description of study

The 5-year K01 Mentored Research Scientist proposal will employ brain, neurocognitive, and computational tools (e.g., machine learning) to understand the impact of opioid-use disorder (OUD) and common co-occurring issues on executive function and clinical outcomes.

Detailed description of study

The 5-year K01 Mentored Research Scientist proposal will employ brain, neurocognitive, and computational tools to understand the impact of opioid-use disorder (OUD) and common co-occurring issues on executive function and clinical outcomes. There have been record numbers of fatal and non-fatal overdoses (ODs) associated with opioids (and other drugs) in the past 12-months. Improving classification and predictive capabilities to enhance treatment and prevent relapse is of the upmost importance. Deficits in neurocognition often are associated with poor treatment outcomes (e.g., more drug use, medication non-adherence), yet co-occurring issues associated with OUD (e.g., depression, anxiety, physical/sexual abuse, neglect) make it difficult to parse which contributing factors lead to worse executive function (EF) and poorer treatment outcomes. Novel brain, neurocognitive, and computational tools are needed to help determine these differences, in order to lay the foundation for better treatments. This need has shaped both the training plan and the associated research project in a 5-year K01 Mentored Research Scientist proposal, building on Dr. Regier's prior preclinical and clinical addiction neuroscience experience (focused mostly on cocaine-use disorders, cue-reactivity, subcortical networks, prior adversity, and univariate imaging techniques)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Opioid use disorder,Healthy controls
  • Age: Between 18 Years - 60 Years
  • Gender: All

Inclusion
  • Men and women with moderate to severe opioid use disorder by DSM-V criteria on a stable (at least one week without change) dose of any buprenorphine-naloxone or methadone.
  • Eligible participants will be between the ages of 18-60 years; able to read at an eighth-grade level; and able to speak English
Exclusion
  • Unable to understand or complete the tasks; this includes inability to understand or complete tasks due to intoxication, English language deficits, etc.
  • Certain mental health conditions determined by the PI to interfere with study participation.

Updated on 24 Apr 2024. Study ID: 854332

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center